Form D · Biotechnology

Blade Therapeutics, Inc.

South San Francisco, CA · CIK 0001677379

Offering snapshot reported Oct 24, 2019 · SEC filing

Reported sold
$38M
Offering amount: $50M
Investors reported
10
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 8, 2018
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 24, 2019Initial$37,999,992No comparison10SEC filing
Oct 24, 2019Initial$11,980,376No comparison21SEC filing
Jun 20, 2016Initial$27,069,454No comparison10SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-351771

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
N/ANone

Source: Form D, filed Oct 24, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Rana Al Hallaq Director
M. Shirley Chiang Executive
Luke Evnin Director
Prabha Ibrahim Executive
Elaine Jones Director
Lloyd B. Klickstein Director
Gary Patou Executive
Wendye Rae Robbins Director, Executive
James Scopa Director
William V. Slattery Director
Peter Van Vlasselaer Director
Cameron Wheeler Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
442 Littlefield Avenue
South San Francisco, CA, 94080